+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID06472713

Phase 2 Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Adults With Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma

Led by Ming-Yuan Chen · Updated on 2025-01-13

32

Participants Needed

1

Research Sites

99 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of combining mitoxantrone hydrochloride liposome injection with PD-1 blockade in patients with recurrent or metastatic nasopharyngeal carcinoma NPC who have not responded to at least one first-line platinum-based treatment andor anti PD-1L1 therapy. This Phase 2, single-arm study includes patients with recurrent NPC that cannot be treated locally or metastatic disease, focusing on those who have failed previous standard treatments. Participants will receive mitoxantrone hydrochloride liposome injection at a dose of 30 mg every 3 weeks for up to 8 cycles. This treatment is combined with PD-1 blockade using one of several drugs tislelizumab, carrellimab, or toripalimab administered every 3 weeks for two years or until certain conditions occur, such as disease progression or unacceptable side effects. After completing the combination treatment cycles, patients continue with PD-1 blockade alone on the same schedule for up to two years. Throughout the study, patients will have regular visits and imaging tests to assess treatment response and safety. Researchers will monitor outcomes such as the objective response rate, duration of response, disease control rate, progression-free survival, and overall survival over an average of two years. Treatment will continue until progression, toxicity, withdrawal, or other specified endpoints. The total participation duration depends on each patients response and tolerance to the study drugs.

CONDITIONS

Brief Title

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Research Team

M

Mingyuan Chen, Doctor

J

Jijin Yao, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here